한빛사논문 | BRIC

방영주 님의 논문 목록

서울대학교 의과대학

CV File 91 kb

Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells
- Oncogene, Published: 17 June 2003;22, 3943–3951 | doi:10.1038/sj.onc.1206573
- 2003-06
- 의약학
- 상위피인용논문
- 방영주(서울대학교 의과대학)
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- Ann. Oncol., Volume 29, Issue 10, October 2018, Pages 2052-2060 | https://doi.org/10.1093/annonc/mdy264
- 2018-10
- 의약학
- 상위피인용논문
- 방영주(서울대학교 의과대학)
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- Invest. New Drugs, December 2011, Volume 29, Issue 6, pp 1449-1458 | https://doi.org/10.1007/s10637-010-9438-y
- 2011-12
- 의약학
- 상위피인용논문
- 방영주(서울대학교 의과대학)
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- Gastric Cancer, July 2015, Volume 18, Issue 3, pp 476-484 | https://doi.org/10.1007/s10120-014-0402-y
- 2015-07
- 의약학
- 상위피인용논문
- 방영주(서울대학교 의과대학)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- Lancet Oncol., Available online 2 November 2017 | https://doi.org/10.1016/S1470-2045(17)30682-4
- 2017-11
- 의약학
- 한빛사논문, 상위피인용논문
- 방영주(서울대학교 의과대학)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- J. Clin. Oncol., July 1, 2014, vol. 32 no. 19 2039-2049 | doi: 10.1200/JCO.2013.53.6136
- 2014-07
- 의약학
- 상위피인용논문
- 방영주(서울대학교 의과대학)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- Lancet Oncol., Available online 3 May 2016 | doi:10.1016/S1470-2045(16)00175-3
- 2016-05
- 의약학
- 한빛사논문, 상위피인용논문
- 방영주(서울대학교 의과대학)
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- J. Clin. Oncol., Published online before print August 17, 2015 | doi: 10.1200/JCO.2014.60.0320
- 2015-08
- 의약학
- 한빛사논문, 상위피인용논문
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
- Lancet Oncol., Available online 15 October 2014 | doi:10.1016/S1470-2045(14)70473-5
- 2014-10
- 의약학
- 한빛사논문, 상위피인용논문
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- Lancet, Volume 379, Issue 9813, Pages 315 - 321, 28 January 2012 | doi:10.1016/S0140-6736(11)61873-4
- 2012-01
- 의약학
- 한빛사논문, 상위피인용논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기